Corcept Therapeutics (NASDAQ: CORT) is facing intense investor scrutiny after a major regulatory setback halved its stock price and prompted shareholder lawsuits. On December 31, 2025, the FDA rejected Corcept’s New Drug Application (NDA) for its lead pipeline drug, relacorilant, citing insufficient evidence of efficacy (www.prnewswire.com). This surprise FDA setback triggered a one-day 50% stock plunge (from $70.20 to $34.80) and erased about $3.6 billion in market value (www.prnewswire.com). In the aftermath, multiple law firms have filed class action suits alleging that Corcept misled investors about relacorilant’s approval prospects (www.globenewswire.com). Below we deep-dive into Corcept’s financial profile, capital structure, valuation, and the key risks and red flags that investors should weigh as a class action and strategic uncertainties loom.
Dividend Policy & Shareholder Returns
Corcept has never paid a cash dividend on its common stock and does not anticipate doing so in the foreseeable future (ir.corcept.com). The company instead returns capital to shareholders via stock repurchases. In 2024, Corcept’s board authorized a $200 million buyback program, under which the company spent about $38.0 million repurchasing shares during the year (www.businesswire.com). This effort accelerated in 2025 – Corcept bought back $245.9 million of its stock that year (www.biospace.com), a sizable outlay funded entirely from internal cash reserves. These buybacks suggest management’s confidence in the company’s long-term prospects and provided support to the stock (especially prior to the late-2025 crash). However, with no dividend, Corcept’s shareholder yield hinges solely on such buybacks, which may fluctuate depending on cash flow and strategic needs.
Leverage, Debt Maturities & Coverage
Financial leverage is minimal – Corcept carries no meaningful debt on its balance sheet. Its latest audited balance sheet shows no short- or long-term borrowings, only accounts payable and lease liabilities, underscoring a debt-free capital structure (ir.corcept.com). In fact, Corcept’s cash and investments totaled $532.4 million as of December 31, 2025 (www.biospace.com), providing a substantial liquidity cushion. With no debt maturities to worry about, the company’s interest coverage is not an issue – Corcept actually earns interest income on its cash (over $24 million in 2024) rather than paying interest expense (ir.corcept.com). This conservative balance sheet gives Corcept flexibility to fund R&D or weather setbacks (like the FDA delay) without creditor pressure. The flip side is that return on equity can appear modest due to the large cash holdings, and shareholders might question if excess cash should be better deployed (e.g. more buybacks or investments) if growth opportunities falter.
Meet the Panel — One Night Only
Financial Performance & Valuation
Corcept’s core business – the drug Korlym for hypercortisolism (Cushing’s syndrome) – has been profitable and growing. Revenue in 2024 was $675.0 million, up 40% from 2023 as more patients were treated (www.businesswire.com). Growth moderated in 2025 with full-year revenue reaching $761.4 million (+13% YoY) (www.biospace.com), as the company likely began to hit saturation in the Cushing’s market and faced rising competition. Net income, however, declined to $99.7 million in 2025 (from $141.2 million in 2024) (www.biospace.com). Heavier R&D and legal expenses weighed on profits, shrinking net margins to about 13%.
Despite the recent drop, Corcept’s valuation remains elevated relative to its current earnings. At a share price around $35, the stock trades at roughly 28× trailing 2024 earnings (EPS of $1.23) (www.businesswire.com) and ~35× 2025 earnings (EPS of $0.82) (www.biospace.com). Its enterprise value of ~$3.0 billion (market cap minus net cash) is about 4× 2025 sales, which is rich for a company relying on essentially one commercial product. By comparison, large pharmaceutical firms often trade at lower multiples, though high-growth or orphan drug biotechs can command premium valuations. Investors appear to still price in future growth from Corcept’s pipeline. Indeed, management had issued aggressive 2025 guidance of $900–950 million revenue (www.businesswire.com) (which the company ultimately missed by a wide margin), and is targeting $900+ million in 2026 sales (www.biospace.com). If Corcept’s new drugs succeed (see below), earnings could expand to justify the valuation – but any further disappointments may compress these multiples. In short, Corcept is not a cheap stock on current fundamentals, so the bull case hinges on pipeline realization rather than undervaluation of the existing business.
Risks & Red Flags
– Regulatory Setback & Pipeline Uncertainty: The FDA’s rejection of relacorilant is a major risk factor. The Complete Response Letter (CRL) indicated that the agency “could not arrive at a favorable benefit-risk assessment for relacorilant” without additional evidence of effectiveness (www.prnewswire.com). This implies Corcept must conduct further clinical trials or analyses, delaying any approval in Cushing’s syndrome. There is no guarantee the additional trials will succeed. This setback not only defers potential revenue, but also casts doubt on the credibility of management’s projections, since executives had repeatedly indicated confidence that relacorilant’s data were “powerful” and that approval was likely (www.globenewswire.com). The episode highlights the inherent pipeline risk in Corcept’s R&D – the company’s next growth driver is now in limbo.
– Product Concentration & Competition: Corcept’s revenue is almost entirely dependent on Korlym (mifepristone), leaving it heavily exposed if this franchise weakens. Competition is emerging on two fronts. First, generic challengers are moving in: a U.S. district court ruled in late 2023 that Teva’s generic version of Korlym does not infringe Corcept’s patents (ir.corcept.com), potentially clearing the way for generic entry once legal appeals are exhausted. Corcept is appealing that decision, but if it ultimately loses, a low-cost generic mifepristone could rapidly erode Korlym sales. Second, new Cushing’s therapies are on the market. Notably, Xeris Biopharma’s drug Recorlev® (levoketoconazole) was approved to treat endogenous Cushing’s and launched in 2022 (ir.corcept.com). Recorlev and other steroidogenesis inhibitors provide alternative treatment options, which could pressure Korlym’s growth or pricing. If Korlym’s patient share or pricing power declines (due to generics or competitors), Corcept’s financial outlook would deteriorate sharply absent a successful new drug to diversify its revenue.
– Securities Litigation & Corporate Governance: The new class action lawsuit adds legal and reputational risk. Plaintiffs accuse Corcept and its executives of misleading investors about relacorilant’s prospects – for example, by stating there were “no impediments” to FDA approval and that “relacorilant is approaching approval” during 2024–2025 (www.globenewswire.com). When the FDA’s negative decision came to light, the stock plunge inflicted heavy investor losses, hence the allegation of securities fraud. While such shareholder suits are not uncommon after biotech setbacks, they can distract management and potentially lead to settlement costs (though often covered by insurance). In Corcept’s case, it has a history of shareholder litigation – it settled a prior class action in 2023 for $14 million (paid entirely by insurers) stemming from past disclosure issues (ir.corcept.com). This pattern of lawsuits is a red flag suggesting possible shortcomings in communication or governance. Additionally, Corcept’s insiders (officers and directors) collectively own about 21% of the company’s stock (ir.corcept.com). Such insider control can be double-edged: it aligns management with shareholder interests, but also means insiders can heavily influence votes and strategic decisions. This might entrench current leadership and make it harder for outside shareholders to press for changes if performance falters.
– Short-Seller Allegations: Corcept has been on the radar of short sellers in the past, raising further red flags. Critics have questioned the company’s business practices – for instance, alleging that Corcept aggressively promoted off-label Korlym use and engaged in patent maneuvers to prolong its monopoly (www.markmanadvisors.com). Corcept even acknowledged the impact of short-seller reports in its SEC filings, warning that short sellers often publish negative opinions “made to appear as if they were objective journalism or unbiased research” (ir.corcept.com). While these allegations are not proven wrongdoing, the very presence of persistent short-seller scrutiny indicates that aspects of Corcept’s operations (pricing, marketing, IP strategy) have appeared questionable to some investors. This adds an extra layer of risk, as unfavorable reports or rumors could hurt the stock’s reputation and valuation.
Open Questions & Outlook
Looking ahead, Corcept faces several critical questions that will determine its trajectory:
– Can relacorilant still secure FDA approval for Cushing’s? Management insists they are “engaged with the FDA to determine the best path forward” for the relacorilant NDA and remains “confident that the ultimate outcome will be approval.” (www.biospace.com). However, it is unclear what additional data the FDA needs and how long new trials might take. Investors are waiting to see if Corcept can address the efficacy (and any safety) concerns to eventually bring this drug to market – or if the program might be scaled back. The timing of any resubmission remains an open question, making it hard to forecast when (or if) relacorilant could start generating revenue in the Cushing’s indication.
– What will be the outcome of relacorilant’s oncology trials and approvals? In an interesting twist, Corcept is also pursuing relacorilant for cancer therapy. The company completed a Phase 3 trial (ROSELLA) of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer with positive results, and the FDA has accepted an NDA for this use – assigning a PDUFA target date of July 11, 2026 (www.biospace.com). An approval here would open a new market and revenue stream, partially offsetting the Cushing’s setback. Similarly, Corcept expects a decision from European regulators on this ovarian cancer therapy by late 2026 (www.biospace.com). The big question is whether relacorilant can gain traction in oncology – a highly competitive arena. If approved, how quickly can Corcept commercialize it and what peak sales could it achieve? Success in oncology could validate Corcept’s cortisol-modulation approach and boost growth; failure or regulatory delays would leave the company even more dependent on Korlym.
– How imminent is generic Korlym, and what is Corcept’s plan to defend its franchise? The threat of a generic mifepristone looms large. Corcept has appealed the patent verdict that favored Teva’s generic, calling the court’s decision “erroneous” and expecting it to be reversed on appeal (ir.corcept.com). Until the appeal is resolved (likely in late 2024 or 2025), Teva’s generic launch is on hold. If Corcept loses the appeal, a generic could launch as early as 2026, dramatically undercutting Korlym’s price. How will Corcept respond? The company has settled past patent disputes (e.g. with Hikma in 2022) – might it strike a deal with Teva to delay entry? Is Corcept developing next-generation formulations or alternative therapies to transition patients (such as dazucorilant for other conditions)? The timing and impact of generic competition remain uncertain, but this issue is pivotal to Corcept’s future earnings. Investors will be watching for any updates on patent litigation or generic entry in the coming quarters.
– What is the likely resolution of the new class action lawsuit? While the lawsuit’s allegations are serious, it’s too early to predict outcomes. In the best case for Corcept, the case could be dismissed or settled without material financial impact (as the 2019 suit was settled via insurance (ir.corcept.com)). However, if the case progresses, discovery could unearth unfavorable information about Corcept’s communications with the FDA or investors. Any protracted legal battle might also distract management. This open question will hover in 2026: whether the class action uncovers any governance issues or forces changes in how the company provides guidance and disclosures.
– Will capital allocation shift in light of recent events? Corcept has been aggressively buying back stock (nearly $246 million in 2025 alone) (www.biospace.com). With the share price now depressed (~50% off its high), one might expect buybacks to continue – yet the company must also conserve cash for running new trials and potential revenue shortfalls. It’s unclear if Corcept’s board will slow the repurchase program to prioritize R&D investments, or view the stock’s drop as an opportunity to buy back even more shares on the cheap. Any changes to capital allocation strategy (e.g. buyback pace, potential future dividends, or external investments) will be an important signal of management’s confidence and priorities in 2026.
In summary, Corcept Therapeutics enters 2026 at a crossroads. The company enjoys a strong balance sheet and a profitable niche drug, but is grappling with significant challenges: a high-profile FDA setback, looming generic competition, and now a cloud of investor litigation. Valuation remains contingent on pipeline success – meaning the next 12–18 months (with an ovarian cancer approval decision and potential re-filing of relacorilant for Cushing’s) are make-or-break for the growth thesis. Investors should closely monitor regulatory updates and legal developments. If Corcept can regain FDA trust and diversify its product line, the current crisis may prove a temporary setback; if not, the “alert” in our title could foreshadow deeper troubles for this single-product biotech. As the class action unfolds and the FDA dialogue continues, transparency from management will be key to rebuilding investor confidence in the wake of 2025’s surprises.
Sources: Corcept Therapeutics SEC filings and earnings releases; FDA and legal disclosures; GlobeNewswire and PR Newswire releases on class action filings; Corcept investor relations news (ir.corcept.com) (www.biospace.com) (www.prnewswire.com) (www.prnewswire.com) (www.globenewswire.com) (www.biospace.com) (ir.corcept.com) (ir.corcept.com) (ir.corcept.com) (ir.corcept.com) (ir.corcept.com).
For informational purposes only; not investment advice.
